SCHEMBL607069

SCHEMBL607069

OC(CN1CCN(Cc2ccc(F)cc2)CC1)Cn1c2ccccc2c2cc(-c3ccc(OC(F)(F)F)cc3)ccc21

nearest known ligand 0.60

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.60
MAPK1 P28482 2/20 0.60
HTT P42858 2/20 0.60
MAPT P10636 2/20 0.58
SMN1; SMN2 Q16637 1/20 0.58
GAA P10253 1/20 0.56
CACNA1G O43497 5/20 0.45
KCNH2 Q12809 3/20 0.45
RAD52 P43351 2/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
DNM1 Q05193 2/20 0.44
POLB P06746 1/20 0.44
TP53 P04637 1/20 0.43
THRB P10828 1/20 0.43
ATM Q13315 1/20 0.43
ALDH1A1 P00352 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL606533 0.89 LMNA (0.68) LMNAMAPK1HTTMAPTSMN1; SMN2
SCHEMBL608732 0.88 LMNA (0.59) LMNAMAPK1HTTMAPTSMN1; SMN2
SCHEMBL7649596 0.84 ALDH1A1 (0.42) LMNAMAPK1HTTMAPTSMN1; SMN2
SCHEMBL5024631 0.83 LMNA (0.57) LMNAMAPK1HTTMAPTSMN1; SMN2
SCHEMBL608283 0.83 LMNA (0.81) LMNAMAPK1HTTMAPTSMN1; SMN2
SCHEMBL608271 0.82 LMNA (0.58) LMNAMAPK1HTTMAPTSMN1; SMN2
SCHEMBL608269 0.81 LMNA (0.67) LMNAMAPK1HTTMAPTSMN1; SMN2
SCHEMBL607210 0.80 MEN1 (0.69) LMNAMAPK1HTTMAPTSMN1; SMN2
SCHEMBL607474 0.76 LMNA (1.00) LMNAMAPK1HTTMAPTSMN1; SMN2
SCHEMBL5022852 0.75 BAX (0.63) LMNAMAPK1HTTMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1237887-B1 9-(PIPERAZINYLALKYL)CARBAZOLES AS BAX-MODULATORS SERONO LAB (CH) 2008-06-04 EP claimed
EP-1237887-A1 9-(PIPERAZINYLALKYL)CARBAZOLES AS BAX-MODULATORS Applied Research Systems ARS Holding N.V. (AN) 2002-09-11 EP claimed
WO-2001029028-A1 9- (PIPERAZINYLALKYL) CARBAZOLES AS BAX-MODULATORS APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2001-04-26 WO claimed
US-8410110-B2 9-(piperazinylalkyl) carbazoles as Bax-modulators MERCK SERONO SA (CH) 2013-04-02 US disclosed
US-20120040933-A1 9-(PIPERAZINYLALKYL) CARBAZOLES AS BAX-MODULATORS APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2012-02-16 US disclosed
US-8053436-B1 9-(piperazinylalkyl) carbazoles as bax-modulators MERCK SERONO SA (CH) 2011-11-08 US disclosed
EP-1237887-B1 9-(PIPERAZINYLALKYL)CARBAZOLES AS BAX-MODULATORS SERONO LAB (CH) 2008-06-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120040933-A1 9-(PIPERAZINYLALKYL) CARBAZOLES AS BAX-MODULATORS BCL2, BAX, BAD LMNA 55/4885MAPK1 3036/4885HTT 65/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.